Physician profile
Kenneth Robert Blank
NPI 1205864964
$1,565.99
in general payments reported to CMS, 2019-2025
33 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2021: $12.86 · 2022: $255 · 2023: $662 · 2024: $153 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $205.41 | 2022-2025 | Libtayo |
| Varian Medical Systems, INC. | $142.14 | 2019 | |
| Merck Sharp & Dohme LLC | $117.01 | 2023-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $112.07 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $87.00 | 2023 | Myfembree |
| Daiichi Sankyo INC. | $85.91 | 2022-2025 | Enhertu |
| Janssen Biotech, INC. | $85.39 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Astellas Pharma US INC | $63.54 | 2025 | Veozah |
| Pharmacosmos Therapeutics INC. | $56.77 | 2023-2024 | Monoferric, Cosela |
| Myovant Sciences INC. | $52.23 | 2022 | |
| Telix Pharmaceuticals | $44.52 | 2023-2025 | Illuccix |
| Bayer Healthcare Pharmaceuticals INC. | $42.54 | 2023 | |
| Myriad Genetic Laboratories, INC. | $42.47 | 2023-2025 | Precisetumor |
| Lilly USA, LLC | $39.98 | 2023-2025 | Jaypirca, Verzenio |
| Incyte Corporation | $33.87 | 2024-2025 | Jakafi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $33.64 | 2025 | Givlaari |
| Novartis Pharmaceuticals Corporation | $30.45 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.39 | 2021-2023 | Entyvio |
| Siemens Medical Solutions USA, INC. | $28.91 | 2023 | Truebeam |
| Astrazeneca Pharmaceuticals LP | $19.38 | 2024 | Lynparza |
| Cumberland Pharmaceuticals, INC. | $19.38 | 2025 | Sancuso |
| Aveo Pharmaceuticals, INC. | $18.52 | 2023 | Fotivda |
| Abbvie INC. | $17.55 | 2025 | |
| Genentech USA, INC. | $17.49 | 2023 | Polivy |
| Amgen INC. | $17.00 | 2023 | Tezspire |
| Genmab U.S., INC. | $16.95 | 2023 | Tivdak |
| Tersera Therapeutics LLC | $16.62 | 2022 | |
| Blueprint Medicines Corporation | $16.21 | 2023 | Ayvakit |
| Glaxosmithkline, LLC. | $15.83 | 2023 | Jemperli, Zejula |
| Puma Biotechnology, INC. | $14.86 | 2025 | |
| Emd Serono, INC. | $14.77 | 2023 | Bavencio |
| Alexion Pharmaceuticals, INC. | $13.86 | 2023 | Ultomiris |
| Eisai INC. | $13.33 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Blank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.